Unichem Laboratories Ltd plans to return to its shareholders more than 50% of net proceeds it will receive from the sale of domestic formulations business to Torrent Pharmaceuticals Ltd. It will use the rest to expand its international business, particularly in the US.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
